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Abstract
Background: There are limited data on accelerated partial breast irradiation (APBI) using external beam techniques.
Moreover, there are recent reports of increased fibrosis and unacceptable cosmesis with APBI using external beam
with BID fractionation. We adopted a once daily regimen of APBI with fractionation similar to that shown to be
effective in a Canadian randomized trial of whole breast irradiation. It is unclear whether patients with DCIS or
invasive lobular carcinoma (ILC) are suitable for APBI.
Methods: The retrospective cohort included 310 patients with 312 tumors of T1-T2N0-N1micM0 invasive ductal
carcinoma (IDC), ILC, or Tis (DCIS) treated with APBI via external beam. Most patients were treated using IMRT with
16 daily fractions of 270 cGy to a dose of 4320 cGy. The target volume included the lumpectomy cavity plus 1.0
cm to account for microscopic disease and an additional 0.5 to 1.0 cm for setup uncertainty and breathing motion.
Ipsilateral breast failure (IBF) was pathologically confirmed as a local failure (LF) or an elsewhere failure (EF).
Results: Median follow-up was 49 months. Among the 312 cases, 213 were IDC, 31 ILC, and 68 DCIS. Median
tumor size was 1.0 cm. There were 9 IBFs (2.9%) including 5 LFs and 4 EFs. The IBF rates among patients with IDC,
ILC, and DCIS were 2.4%, 3.2%, and 4.4%, respectively, with no significant difference between histologies. When
patients were analyzed by the ASTRO APBI consensus statement risk groups, 32% of treated cases were considered
suitable, 50% cautionary, and 18% unsuitable. The IBF rates among suitable, cautionary, and unsuitable patients
were 4.0%, 2.6%, and 1.8%, respectively, with no significant difference between risk groups. Acute skin reactions
were rare and long-term cosmetic outcome was very good to excellent.
Conclusions: External beam APBI with once daily fractionation has a low rate of IBF consistent with other
published APBI studies. The ASTRO risk stratification did not differentiate a subset of patients with a higher rate of
IBF. APBI may be an appropriate treatment for women with DCIS and ILC.
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Introduction
APBI can be delivered by several techniques and has
been explored to treat early stage breast cancer patients
in recent years without definitive long-term data from
randomized clinical trials. There are phase I/II/III trials,
multi-, and single institution studies showing acceptable
outcomes with limited follow-up using multicatheter
brachytherapy [1-3], MammoSite brachytherapy [4-6],
intraoperative radiation therapy [7-9], and more recently
external beam radiation therapy via 3D conformal radio-
therapy (3D-CRT) [10,11]. The last approach is the
most commonly used method for APBI in the phase III
NSABP B39 randomized trial with over two-thirds of
patients receiving treatment with this modality.
There is no uniform agreement about which patients
are suitable candidates for APBI. Many investigators
limit APBI to early stage invasive ductal carcinoma
(IDC) < 3 cm in size with lymph node negative disease.
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lobular carcinoma (ILC) are suitable for APBI. ASTRO
has formulated a consensus statement on APBI based
on limited published literature and divided patients into
suitable, cautionary, and unsuitable groups [12]. Factors
such as age, T stage, N stage, margin status, ER status,
LVI, ductal or lobular histology, presence of pure DCIS,
EIC, and multifocality/multicentricity were used to clas-
sify patients.
In the NSABP B39 trial, patients receiving APBI via
external beam are treated with a dose fractionation regi-
men of 3.85 Gy BID for a total of 10 fractions. In a sur-
vey of our patients offering BID versus once daily
fractionation, patients clearly preferred once daily treat-
m e n t .T h u s ,w ea d o p t e dao n c ed a i l yr e g i m e no f2 . 7 0
Gy for 16 fractions to a total dose of 43.2 Gy. This
scheme is similar to that demonstrated by Whelan et al
to be equivalent to 50.4 Gy in 1.80 Gy daily fractions in
terms of efficacy and cosmesis [13]. We herein report
the results of a large retrospective single institution
study of once daily external beam APBI for early stage
breast cancer.
Materials and methods
Patients
Between November 1, 2002, and June 30, 2009, 339
patients with 341 tumors of T1-T2N0-N1micM0 IDC,
ILC, or Tis (DCIS) were treated with APBI via external
beam at four facilities of the NorthShore University
HealthSystem. Of the 339 patients, 310 patients with
312 tumors with a minimum of one year follow-up
comprised the institutional review board-approved ret-
rospective study cohort. The pretreatment patient char-
acteristics are listed in Table 1.
Simulation, treatment planning, and treatment
All patients underwent CT simulation in the supine
position with a breast board for immobilization. CT
images were acquired with 3 mm slice thickness. The
clinical target volume (CTV) included the CT-defined
lumpectomy cavity and surgical clips when present plus
a 1.0 cm margin. The CTV was limited to 3-5 mm from
the skin surface and manually edited to exclude the
anterior chest wall and pectoralis muscle or, alterna-
tively, limited to 5 mm from the lung-chest wall inter-
face. The planning target volume (PTV) included the
CTV plus a 0.5 to 1.0 cm margin to account for setup
uncertainty and breathing motion. The PTV was limited
to 3 mm from the skin surface.
Treatment planning was performed using either
Eclipse (Varian Medical Systems, Palo Alto, CA) or Xio
(CMS, St. Louis, MO) software with inverse planning-
based beamlet IMRT. Field angles were similar to breast
tangents with the addition of AP, lateral, and/or oblique
Table 1 Pretreatment patient characteristics
Characteristic Value
Age (years)
Median 73
Range 42-89
Tumor size (cm)
Median 1.0
Range 0.1-3.5
Histology
Invasive ductal 213 (68%)
Invasive lobular 31 (10%)
DCIS 68 (22%)
Grade
Grade 1 142 (46%)
Grade 2 114 (37%)
Grade 3 53 (17%)
Not stated 3 (1%)
Invasive tumors - EIC present
Yes 34 (14%)
No 206 (84%)
Not stated 4 (2%)
Invasive tumors - LVI present
Yes 5 (2%)
No 235 (96%)
Not stated 4 (2%)
DCIS tumors - Necrosis present
Yes 36 (53%)
No 28 (41%)
Not stated 4 (6%)
Nodal Status of invasive cancer
N0 207 (85%)
N1 2 (1%)
Nx 35 (14%)
ER/PR status
Positive 282 (90%)
Negative 23 (7%)
Not stated 7 (2%)
HER-2/neu status of invasive cancer
Positive 11 (5%)
Negative 231 (95%)
Not stated 2 (1%)
Surgical margins
Negative (≥ 2 mm) 264 (85%)
Close (< 2 mm) 41 (13%)
Positive 7 (2%)
Chemotherapy
Yes 7 (2%)
No 305 (98%)
Hormonal therapy
Yes 166 (53%)
No 146 (47%)
Abbreviations: EIC = extensive intraductal component; LVI = lymphovascular
invasion
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coplanar fashion. Doses were calculated using inhomo-
geneity corrections. Dose-volume histograms (DVHs)
were calculated for each patient. Planning guidelines
were to cover the CTV with the 100% isodose line and
the PTV with the 95% isodose line. The maximum hot
spot was limited to 110%. Normal tissue guidelines were
to limit 50% of the ipsilateral breast volume to less than
50% of the prescribed dose and 33% of the ipsilateral
breast volume to less than 100% of the prescribed dose.
It was recommended that the heart and lung DVHs fall
below that for whole breast tangent fields.
Radiation treatments began 3 to 8 weeks after surgery.
Treatment was delivered using Varian linear accelerators
with 6, 10, and/or 15 MV photons. Most patients were
treated with 16 fractions of 270 cGy delivered once daily
five days a week for a total dose of 4320 cGy. Certain
patients with superficial anteromedial lumpectomy sites
were treated with en face 6 or 9 MeV electrons using 18
fractions of 250 cGy for a total dose of 4500 cGy. Bolus
was occasionally used with electrons at the discretion of
the treating physician.
Follow-up
Patients were seen and examined by the treating physi-
cian 4-6 weeks after the completion of radiation and by
members of the treatment team (surgical and medical
oncologists) every 3-6 months for the first five years and
yearly thereafter. Mammography was performed every
6-12 months. An ipsilateral breast failure (IBF) was
defined as a pathologically confirmed recurrence of
invasive carcinoma or DCIS in the treated breast. A
recurrence was classified as a local failure (LF) if located
in the treated breast quadrant or an elsewhere failure
(EF) if located in a different quadrant.
Toxicity
Acute skin toxicity was evaluated during and at the end
of treatment. Cosmetic outcome was evaluated by the
treating physician at follow-up visits. Toxicity was
scored based on the NCI CTCAE v3.0 toxicity scale.
Statistical methods
The follow-up time interval was calculated from the
date of completion of the radiation treatments. Associa-
tions between clinical, pathologic, and treatment-related
variables and clinical events were analyzed using log-
rank regression. Between-group differences with respect
to time-to-recurrence were depicted with Kaplan-Meier
curves and using a log-rank test. A p value less than or
equal to 0.05 was regarded as statistically significant.
SAS 9.2 (Cary, NC) was used to carry out all statistical
analyses.
Results
The pretreatment patient characteristics are listed in
Table 1. The median age at treatment was 73 with a
range of 42 to 89. Most patients (68%) had IDC; 10%
h a dI L Ca n d2 2 %h a dD C I S .T h em e d i a no v e r a l lt u m o r
size was 1.0 cm with a range of 0.1 to 3.5 cm. The
tumors were grade 1 in 46%, grade 2 in 37%, and grade
3 in 17%. Of those patients with invasive cancer, 86%
underwent sentinel lymph node biopsy with the vast
majority (99%) being N0 and 1% having N1mic disease.
Ninety percent of tumors were ER/PR positive; 53%
received hormonal therapy with tamoxifen or an aroma-
tase inhibitor. Twelve patients (4%) had HER-2/neu
positive invasive tumors. Seven patients (2%) received
chemotherapy.
Nintety-five percent of patients received treatment
with IMRT. Thirteen patients (4%) received treatment
with en face electrons due to superficial anteromedial
lumpectomy sites. Two patients (1%) received treatment
with 3D-CRT. Three patients had received prior whole
breast irradiation (WBI) for DCIS or invasive cancer at
an average of 11.3 years before treatment with APBI.
Median follow-up was 49 months with a range of 12
to 97 months. In the 312 treated breasts, there were 9
IBFs (2.9%). Of these recurrences, 5 were LFs (1.6%)
that occurred at a median of 45 months after treatment.
Four recurrences (1.3%) developed elsewhere in the
breast and occurred at a median of 39 months after
treatment. All 9 patients with recurrence underwent
mastectomy. One patient with a LF subsequently devel-
oped metastatic disease and died of breast cancer 15
months later.
Three patients (1.0%) developed isolated ipsilateral
axillary lymph node recurrences. Two patients under-
went axillary lymph node dissection and the third had
biopsy confirmation only due to advanced age and then
received hormonal therapy. Four of 310 patients (1.3%)
developed metastatic disease and 3 have died. The over-
all survival was 94.5% and the breast cancer specific sur-
vival was 99.0%. Eleven patients developed contralateral
breast cancers and 21 patients developed other non-
cutaneous malignancies.
The IBF rates according to histology are listed in
Table 2. Among 213 patients with IDC whose median
follow-up was 51 months, the IBF rate was 2.4%; LFs
being 1.4% and EFs 0.9%. Among 31 patients with ILC
whose median follow-up was 39 months, the IBF rate
was 3.2% with only one EF. Among 68 patients with
DCIS whose median follow-up was 48 months, the IBF
rate was 4.4%; LFs being 2.9% and EFs 1.5%. There was
no significant difference in IBF rates between the histol-
ogies (p = 0.691 on log-rank test, Figure 1).
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for APBI are listed in Table 3. When patients were stra-
tified accordingly, 32% of treated cases were considered
suitable, 50% cautionary, and 18% unsuitable. The IBF
rates among suitable, cautionary, and unsuitable patients
were 4.0%, 2.6%, and 1.8%, respectively. There was no
significant difference in IBF rates between the ASTRO
risk groups (p = 0.653 on log-rank test, Figure 2). One
patient in each risk group died of breast cancer.
The clinical and pathologic characteristics of patients
with an IBF are detailed in Table 4. On univariate analy-
sis among all 312 treated cases, IBF was significantly
associated with ER/PR negative status (p = 0.0003).
There was a trend for an association of higher grade
with IBF (p = 0.085). No associations were statistically
significant on multivariate analysis. For patients with
IDC, ER/PR negative status was associated with IBF on
univariate analysis (p = 0.02) but did not remain signifi-
cant on multivariate analysis. For patients with ILC, no
variables were associated with IBF on univariate analysis.
For patients with DCIS, IBF was associated with ER/PR
negative status (p = 0.04), presence of necrosis (p =
0.04), and positive surgical margin (p = 0.001) on uni-
variate analysis. None of these factors was significant on
multivariate analysis.
Acute skin reactions were rare. Grade 0, 1, and 2 skin
reactions occurred in 52%, 41%, and 6% of patients,
respectively. Grade 3 skin reactions occurred in 0.3% of
patients and there was no grade 4 toxicity. Two patients
developed symptomatic seromas requiring drainage (one
during radiotherapy and one in the month following
treatment). Long-term cosmetic outcome was very good
to excellent in all assessed patients. There were no sig-
nificant late toxicities.
Table 2 Treatment outcome according to histology
Histology Number
cases
Median follow-
up (mos)
Ipsilateral breast
failure rate
True local
failure rate
Elsewhere*
failure rate
Number developing
metastatic disease
Number dead of
breast cancer
Invasive
ductal
213 (68%) 51 2.4% 1.4% 0.9% 4 3
Invasive
lobular
31 (10%) 39 3.2% 0 3.2% 0 0
DCIS 68 (22%) 48 4.4% 2.9% 1.5% 0 0
* Elsewhere refers to a recurrence in the ipsilateral breast in a different quadrant than the original lumpectomy site
Figure 1 Freedom from ipsilateral breast failure by histology vs time.
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The IBF rate of 2.9% in our 312 cases with a median fol-
low-up of 4.1 years is similar to recurrence rates in
other published studies. In RTOG 0319, 52 patients
with early stage IDC received external beam APBI using
3.85 Gy BID for ten fractions [10]. The 4-year IBF rate
was 6% (4% LF, 2% EF). In the ASBS MammoSite regis-
try trial, 1,440 patients received intracavitary brachyther-
apy [4]. The 5-year ipsilateral recurrence rate was 3.0%.
Two randomized clinical trials have investigated APBI.
The TARGIT-A trial randomized 2,232 women with
IDC to single fraction low energy photon intraoperative
radiation or WBI [7]. The 4-year local recurrence rates
were 1.20% and 0.95% in the partial breast and whole
breast treatment groups, respectively. In a trial from
Hungary, of 258 patients with early stage IDC rando-
mized to either WBI or partial breast irradiation using
multicatheter brachytherapy or electron beam radiation,
there was no significant difference in 5-year local
recurrence rates: 4.7% and 3.4% for partial and whole
breast treatment groups, respectively [3].
When our data were analyzed according to the
ASTRO APBI risk groups, we observed no correlation
between recurrence rate and risk stratification (Figure
2). A similar finding was observed in the ASBS Mam-
moSite registry trial [14]. The 5-year ipsilateral recur-
rence rates among suitable, cautionary, and unsuitable
patients were 2.6%, 5.4%, and 5.3%, respectively. The
conclusion of this study, like ours, was that the current
ASTRO risk stratification fails to differentiate a subset
of patients with a significantly higher rate of IBF when
treated with APBI. A recent study from University of
Wisconsin evaluated outcomes in 136 patients treated
by intracavitary brachytherapy and classified as caution-
ary according to the ASTRO risk stratification [15].
Although 28% of patients had multiple cautionary risk
factors, the IBF rate was 4.8% at 5 years. Another study
from the Medical University of South Carolina with a
Table 3 Treatment outcome by ASTRO risk stratification for APBI [12]
Risk
Group
Number
cases
Median follow-
up (mos)
Ipsilateral breast
failure rate
True local
failure rate
Elsewhere*
failure rate
Number developing
metastatic disease
Number dead of
breast cancer
Suitable 101 (32%) 52 4.0% 3.0% 1.0% 1 1
Cautionary 156 (50%) 47 2.6% 0.6% 1.9% 2 1
Unsuitable 55 (18%) 51 1.8% 1.8% 0 1 1
* Elsewhere refers to a recurrence in the ipsilateral breast in a different quadrant than the original lumpectomy site
Figure 2 Freedom from ipsilateral breast failure by ASTRO risk group vs time.
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strate a difference in local recurrence rates by ASTRO
risk stratification among 183 patients with early stage
invasive cancers or DCIS when treated with intracavitary
brachytherapy [16]. Although well-intentioned, rapidly
evolving APBI clinical results appear to be making the
ASTRO guidelines for appropriateness unduly
restrictive.
There are few studies reporting outcomes of patients
with DCIS treated by APBI. In our study, 68 patients
had DCIS. With a median follow-up of 48 months, the
IBF rate was 4.4% with 2.9% LF and 1.5% EF. Although
a few factors on univariate analysis (ER/PR negative,
presence of necrosis, positive surgical margin) were
associated with IBF in patients with DCIS, no variable
remained significant on multivariate analysis, albeit with
a small number of events. In the ASBS MammoSite reg-
istry trial, 194 DCIS patients were studied [17]. At 54
months median follow-up, the IBF rate was 3.4% with 3
LFs and 3 EFs. These results are similar to those of
DCIS treated with conventional WBI [18] as well as
invasive cancer treated with APBI [4,10]. In a study
from William Beaumont Hospital, 53 patients with
DCIS were treated with APBI using MammoSite bra-
chytherapy or external beam via 3D-CRT [19]. With a
42 month median follow-up, there was only one local
recurrence. In the University of Wisconsin study, there
were no ipsilateral recurrences in 32 patients with DCIS
treated by intracavitary brachytherapy [15]. Although
follow-up is limited with a low number of DCIS patients
treated with APBI, our study and the available literature
indicate that APBI may be a safe and acceptable treat-
ment for women with DCIS.
Histopathologic studies in ILC have shown these
tumors to be more multicentric than IDC [20,21]. Yet,
similar to ductal cancers, most lobular cancers recur at
o rn e a rt h el u m p e c t o m ys i t e[ 2 2 , 2 3 ] .M a n ys t u d i e so f
APBI exclude lobular histology [1,3-7,10]. Like DCIS,
lobular histology is considered cautionary by the
ASTRO risk stratification for APBI [12]. Furthermore,
lobular histology is not included in the ABS or ASBS
guidelines of appropriate patients for APBI. Not to be
deterred, however, we treated 31 patients with ILC and
did not observe any increased rate of local or elsewhere
recurrence. Although therew a sas m a l ln u m b e ro f3 1
patients and a short median follow-up of 39 months,
there was no LF and only one EF (3.2%). In a recent
study from Germany of 274 women including 45
patients with ILC treated with multicatheter interstitital
brachytherapy, there was no difference in local control
between lobular and ductal histology with a median fol-
low-up of 64 months [24]. Patients with ILC as well as
DCIS are being accrued to the NSABP B39 randomized
trial.
Our once daily dose fractionation scheme is different
than that used in the NSABP B39 trial, where patients
receiving external beam APBI are treated with 3.85 Gy
BID for 10 fractions. However, after a survey of our
patients offering BID versus once daily fractionation
where patients clearly preferred once daily treatment,
we adopted once daily fractionation of 2.70 Gy for 16
fractions to a dose of 43.2 Gy. This fractionation is simi-
lar to that shown by Whelan et al in a Canadian rando-
mized clinical trial of WBI to be equivalent to 50.4 Gy
in 1.80 Gy daily fractions both in terms of efficacy and
cosmesis [13] and is also supported by the results of the
UK START Trial B [25]. A regimen of 2.70 Gy once
daily for fifteen fractions to a dose of 40.5 Gy was even
used with minimal skin toxicity in a study investigating
APBI and concurrent chemotherapy [26]. There are data
with limited follow-up from the prospective RTOG 0319
study to support the BID NSABP B39 trial regimen [10].
However, the dose fractionation of 3.85 Gy BID for 10
fractions may be unnecessarily high for treatment of
low-risk breast cancer patients [27]. There have been
two cautionary reports involving the BID fractionation
Table 4 Characteristics of patients with ipsilateral breast failures
# Original
histology
Age
(y)
Tumor size
(cm)
Margins Grade ER/
PR
Necrosis EIC or
LVI
Hormonal
therapy
Failure
type
Failure
histology
Time to failure
(mos)
1 IDC 64 1.7 Neg 1 Pos N/A No Yes LF IDC 45
2 IDC 65 0.6 Neg 1 Pos N/A No No LF IDC 52
3 IDC 75 1.8 Neg 2 Pos N/A No Yes LF IDC 60
4 IDC 77 0.9 Neg 1 Pos N/A No Yes EF ILC 34
5 IDC 83 1.0 Close 3 Neg N/A No No EF IDC 46
6 ILC 72 0.6 Neg 2 Pos N/A No Yes EF IDC 43
7 DCIS 50 3.0 Pos 3 Neg Yes N/A No LF DCIS 22
8 DCIS 65 0.9 Neg 3 Neg Yes N/A Yes LF DCIS 23
9 DCIS 70 0.4 Neg 3 Pos Yes N/A No EF ILC 33
Abbreviations: IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; LF = local failure at lumpectomy site; EF = elsewhere failure in a different
quadrant than the original lumpectomy site; EIC = extensive intraductal component; LVI = lymphovascular invasion
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Michigan involving APBI using IMRT with 3.85 Gy BID
for 10 fractions, 7 of 32 patients developed unacceptable
cosmesis leading to early study closure [28]. The major-
ity of these patients had treatment plans that adhered to
the dosimetric requirements of the NSABP B39 trial. In
another study from Tufts University, 60 patients
received APBI using 3D-CRT with 3.85 Gy BID for 10
fractions [29]. There was a high rate of moderate to
severe late toxicity, especially subcutaneous fibrosis,
despite adhering to the dosimetric requirements of the
NSABP B39 trial.
In our study, 5 of 9 patients developed an IBF while
taking hormonal therapy. It has been suggested by the
CALGB 9343 randomized trial that hormonal therapy
alone with tamoxifen is sufficient treatment for patients
over age 70 with stage I ER-positive breast cancers [30].
With a median follow-up of 10.5 years, however, the
local recurrence rate with radiation therapy and tamoxi-
fen was significantly lowered to 2% versus 8% in the
tamoxifen alone group. Along with a higher risk of local
recurrence in patients treated with hormonal therapy
alone, there is also the risk of side effects from adminis-
tering hormonal medication for five years in an elderly
patient population. There is a risk of thromboembolic
disease, stroke, endometrial cancer, and hot flashes with
tamoxifen. With an aromatase inhibitor, there is a risk
of bone density loss with increased risk of skeletal frac-
ture, cardiovascular disease, and symptomatic joint dis-
orders. Moreover, patients who experience these side
effects often discontinue medication early without com-
pleting the recommended five year course. In addition
to being more effective than hormonal therapy alone in
early stage breast cancer [31], radiation therapy has
fewer and less serious side effects, and, with APBI, can
be completed in a short time period rather than five
years. A prospective randomized trial of APBI versus
five years of an aromatase inhibitor in women over age
70 might resolve these issues.
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